SCHEMBL8427744

SCHEMBL8427744

CN1CCN(c2ccc(Nc3nccn4c(C5C=NN(C)C5)cnc34)cn2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPKAPK5 Q8IW41 1/20 0.38
▸ JAK2 O60674 3/20 0.37
▸ SYK P43405 2/20 0.37
▸ ADORA3 P0DMS8 1/20 0.36
▸ CTSC P53634 1/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ JAK3 P52333 2/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ JAK1 P23458 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ AURKA O14965 1/20 0.35
▸ MAP4K4 O95819 1/20 0.35
▸ EGFR P00533 1/20 0.34
▸ BTK Q06187 1/20 0.34
▸ WEE1 P30291 1/20 0.34
▸ PTK6 Q13882 1/20 0.34
▸ DGAT1 O75907 1/20 0.33
▸ CCNT1 O60563 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8427844 0.89 KCNH2 (0.36) SYKADORA3AURKABTKPTK6
SCHEMBL8429587 0.88 ADORA3 (0.38) MAPKAPK5ADORA3AURKAMAP4K4EGFR
SCHEMBL8429786 0.88 BTK (0.34) JAK2SYKAURKABTK
SCHEMBL8429895 0.79 PAK4 (0.42) ADORA3AURKAPTK6
SCHEMBL8427933 0.78 ZAP70 (0.35) SYKADORA3AURKAEGFR
SCHEMBL8426788 0.78 AURKA (0.35) MAPKAPK5ADORA3AURKA
SCHEMBL12473231 0.77 AURKA (0.34) MAPKAPK5SYKADORA3AURKA
SCHEMBL8426616 0.76 PAK4 (0.37) SYKADORA3AURKAPTK6
SCHEMBL8427741 0.75 BRD4 (0.39) SYKADORA3KMT2A
SCHEMBL8246793 0.74 AURKA (0.59) MAPKAPK5AURKAMAP4K4PTK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576085-B2 Imidazopyrazines as cyclin dependent kinase inhibitors SCHERING CORPORATION (US) 2009-08-18 — — US disclosed
US-20060106023-A1 Novel imidazopyrazines as cyclin dependent kinase inhibitors SCHERING CORPORATION 2006-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106023-A1 Novel imidazopyrazines as cyclin dependent kinase inhibitors CDK2, CDKN1A, CDK1 MAPKAPK5 148/4885JAK2 143/4885SYK 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback